BTIG Research initiated coverage of Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR) with a Buy rating and a $32.00 price target. The stock price soared $1.80 to close at $9.25.
Coverage initiated on Eiger BioPharmaceuticals
July 14, 2017 at 17:03 PM EDT
